Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.76M Buy
+50,000
New +$2.71M ﹤0.01% 4673
2025
Q4
Sell
-50,000
Closed -$2.16M 10773
2025
Q3
$2.16M Buy
+50,000
New +$1.95M ﹤0.01% 4875
2025
Q2
Sell
-30,000
Closed -$1.16M 10487
2025
Q1
$1.16M Sell
30,000
-237,700
-89% -$8.7M ﹤0.01% 5157
2024
Q4
$9.05M Buy
267,700
+42,800
+19% +$1.54M ﹤0.01% 3168
2024
Q3
$9.19M Buy
+224,900
New +$9.2M ﹤0.01% 2451
2024
Q1
Sell
-24,000
Closed -$889K 9595
2023
Q4
$889K Buy
+24,000
New +$862K ﹤0.01% 4604
2023
Q3
Sell
-52,700
Closed -$1.88M 9651
2023
Q2
$1.88M Hold
52,700
﹤0.01% 3591
2023
Q1
$1.88M Sell
52,700
-62,300
-54% -$2.18M ﹤0.01% 3504
2022
Q4
$4.04M Buy
+115,000
New +$3.83M ﹤0.01% 2702
2022
Q2
Sell
-240
Closed -$13K 10558
2022
Q1
$13K Buy
+240
New +$13K ﹤0.01% 8047
2021
Q4
Sell
-72,800
Closed -$3.48M 10425
2021
Q3
$3.48M Buy
+72,800
New +$3.66M ﹤0.01% 3064
2016
Q4
Sell
-400
Closed -$22K 7867
2016
Q3
$22K Buy
+400
New +$21.9K ﹤0.01% 6220
2016
Q1
Sell
-1,920
Closed -$97K 7841
2015
Q4
$97K Hold
1,920
﹤0.01% 5238
2015
Q3
$92K Sell
1,920
-81,200
-98% -$4.23M ﹤0.01% 5299
2015
Q2
$4.33M Sell
83,120
-3,200
-4% -$180K ﹤0.01% 2221
2015
Q1
$4.98M Buy
86,320
+77,840
+918% +$4.46M ﹤0.01% 2074
2014
Q4
$453K Buy
+8,480
New +$474K ﹤0.01% 4290

Other funds holding GSK

UBS Group's GSK Position: Q1 2026 in Review

UBS Group reduced its GSK (GSK) stake by 67% in Q1 2026, selling an estimated $227M and leaving 2,084,235 shares worth $115M. The position accounts for 0.02% of the portfolio, ranked #948.

UBS Group first reported a position in GSK in Q4 2014 and has held it in 46 quarters since. The position peaked at $308M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • UBS Group held 2,084,235 shares of GSK worth $115M as of Q1 2026.
  • UBS Group sold 4,196,648 GSK shares in Q1 2026, an estimated $227M.
  • GSK made up 0.02% of UBS Group's portfolio in Q1 2026, its #948 holding.
  • UBS Group first reported a position in GSK in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's GSK position peaked at $308M in Q4 2025.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.